Exhibit 3.3
THIRD AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
FOGHORN THERAPEUTICS INC.
Foghorn Therapeutics Inc., a Delaware corporation (the “Corporation”), hereby certifies that this Third Amended and Restated Certificate of Incorporation has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware (the “DGCL”), and that:
A. The name of the Corporation is: Foghorn Therapeutics Inc.
B. The original Certificate of Incorporation of the Corporation was filed with the Secretary of the State of Delaware on October 2, 2015. The Certificate of Incorporation was amended and restated by each of the Certificate of Amendments filed on April 7, 2016, November 28, 2016 and July 19, 2017 and the Second Amended and Restated Certificate of Incorporation filed on December 18, 2018, as amended by each of the Certificate of Amendments filed on January 9, 2019, September 18, 2019, July 17, 2020 and October [22], 2020 (the “Original Certificate of Incorporation”).
C. This Third Amended and Restated Certificate of Incorporation amends and restates the Original Certificate of Incorporation of the Corporation.
D. The Certificate of Incorporation upon the filing of this Third Amended and Restated Certificate of Incorporation, shall read as follows:
ARTICLE I — NAME
The name of the corporation is Foghorn Therapeutics Inc. (the “Corporation”).
ARTICLE II — REGISTERED OFFICE AND AGENT
The address of the Corporation’s registered office in the State of Delaware is located at the Corporate Trust Center, 1209 Orange Street, in the city of Wilmington, County of New Castle, Delaware 19801. The name of the Corporation’s registered agent at such address is The Corporation Trust Company.
ARTICLE III — PURPOSE
The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL.
ARTICLE IV — CAPITALIZATION
(a) Authorized Shares. The total number of shares of stock which the Corporation shall have authority to issue is 200,000,000 shares, consisting of 175,000,000 shares of Common Stock, par value $0.0001 per share (“Common Stock”) and 25,000,000 shares of Preferred Stock,